Smooth Sailing: Definium’s LSD Voyage Hits Primary and Key Secondary Endpoints in GAD
Definium Therapeutics announced positive topline results from its Phase 3 study of LSD (DT120) for generalized anxiety disorder (GAD). This follows positive topline results from its Phase 3 program in major depressive disorder (MDD).
By Josh · Published August 13, 2026
Sourced from psychedelicalpha.com, published August 12, 2026. Cite the original publication, not this page, for the reporting itself.
Definium Therapeutics announced positive topline results from its Phase 3 study of LSD (DT120) for generalized anxiety disorder (GAD). This follows positive topline results from its Phase 3 program in major depressive disorder (MDD).